|
1
|
Stölzel U, Doss MO and Schuppan D:
Clinical guide and update on porphyrias. Gastroenterology.
157:365–381.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pischik E and Kauppinen R: An update of
clinical management of acute intermittent porphyria. Appl Clin
Genet. 8:201–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edel Y and Mamet R: Porphyria: What is it
and who should be evaluated? Rambam Maimonides Med J. 9:2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walterfang M, Bonnot O, Mocellin R and
Velakoulis D: The neuropsychiatry of inborn errors of metabolism. J
Inherit Metab Dis. 36:687–702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phillips JD: Heme biosynthesis and the
porphyrias. Mol Genet Metab. 128:164–177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vilas-Boas S and Corte-Real A: Posterior
reversible encephalopathy syndrome and azathioprine. Eur J Case Rep
Intern Med. 6:0010322019.PubMed/NCBI
|
|
7
|
De Siervi A, Rossetti MV, Parera VE,
Astrin KH, Aizencang GI, Glass IA, Batlle AM and Desnick RJ:
Identification and characterization of hydroxymethylbilane synthase
mutations causing acute intermittent porphyria: Evidence for an
ancestral founder of the common G111R mutation. Am J Med Genet.
86:366–375. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun G, Wang C, Zhen J, Zhang G, Xu Y and
Deng Z: Cloning and sequencing of KIR2DL1 Framework Gene cDNA and
identification of a novel allele. Zhonghua Yi Xue Yi Chuan Xue Za
Zhi. 33:694–697. 2016.(In Chinese). PubMed/NCBI
|
|
9
|
Unzu C, Sampedro A, Mauleón I, Alegre M,
Beattie SG, de Salamanca RE, Snapper J, Twisk J, Petry H,
González-Aseguinolaza G, et al: Sustained enzymatic correction by
rAAV-mediated liver gene therapy protects against induced motor
neuropathy in acute porphyria mice. Mol Ther. 19:243–250. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen B, Solis-Villa C, Erwin AL, Balwani
M, Nazarenko I, Phillips JD, Desnick RJ and Yasuda M:
Identification and characterization of 40 novel hydroxymethylbilane
synthase mutations that cause acute intermittent porphyria. J
Inherit Metab Dis. 42:186–194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Corbett MB: The Watson-Schwartz Test.
JAMA. 195:4811966. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elder GH and Sandberg S: Identifying acute
porphyria in patients with acute polyneuropathy or encephalopathy.
Nat Clin Pract Neurol. 4:648–649. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gill R, Kolstoe SE, Mohammed F, Al D-Bass
A, Mosely JE, Sarwar M, Cooper JB, Wood SP and Shoolingin-Jordan
PM: Structure of human porphobilinogen deaminase at 2.8 A: The
molecular basis of acute intermittent porphyria. Biochem J.
420:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Simon NG and Herkes GK: The neurologic
manifestations of the acute porphyrias. J Clin Neurosci.
18:1147–1153. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fugate JE and Rabinstein AA: Posterior
reversible encephalopathy syndrome: Clinical and radiological
manifestations, pathophysiology, and outstanding questions. Lancet
Neurol. 14:914–925. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ollivier M, Bertrand A, Clarençon F,
Gerber S, Deltour S, Domont F, Trunet S, Dormont D and Leclercq D:
Neuroimaging features in posterior reversible encephalopathy
syndrome: A pictorial review. J Neurol Sci. 373:188–200. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng X, Liu X, Wang Y, Zhao R, Qu L, Pei
H, Tuo M, Zhang Y, Song Y, Ji X, et al: Acute intermittent
porphyria presenting with seizures and posterior reversible
encephalopathy syndrome: Two case reports and a literature review.
Medicine (Baltimore). 97:e116652018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arora S, Young S, Kodali S and Singal AK:
Hepatic porphyria: A narrative review. Indian J Gastroenterol.
35:405–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kurosaki T and Maquat LE:
Nonsense-mediated mRNA decay in humans at a glance. J Cell Sci.
129:461–467. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yasuda M, Gan L, Chen B, Yu C, Zhang J,
Gama-Sosa MA, Pollak DD, Berger S, Phillips JD, Edelmann W and
Desnick RJ: Homozygous hydroxymethylbilane synthase knock-in mice
provide pathogenic insights into the severe neurological
impairments present in human homozygous dominant acute intermittent
porphyria. Hum Mol Genet. 28:1755–1767. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Solis C, Martinez-Bermejo A, Naidich TP,
Kaufmann WE, Astrin KH, Bishop DF and Desnick RJ: Acute
intermittent porphyria: studies of the severe homozygous dominant
disease provides insights into the neurologic attacks in acute
porphyrias. Arch Neurol. 61:1764–1770. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Y, Shen H, Keep RF and Smith DE:
Peptide transporter 2 (PEPT2) expression in brain protects against
5-aminolevulinic acid neurotoxicity. J Neurochem. 103:2058–2065.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fava G, Marucci L, Glaser S, Francis H, De
Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T, et
al: gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by
cyclic AMP-dependent regulation of the protein kinase
A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res.
65:11437–11446. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Z, Shen GQ, Lerner A and Gao B:
Immune system activation in the pathogenesis of posterior
reversible encephalopathy syndrome. Brain Res Bull. 131:93–99.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Olivier P, Van Melkebeke D, Honoré PJ,
Defreyne L and Hemelsoet D: Cerebral vasospasm in acute porphyria.
Eur J Neurol. 24:1183–1187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thachil J: Nitric oxide and the clinical
manifestations of acute porphyria. Intern Med J. 38:732–735. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao B, Lyu C, Lerner A and McKinney AM:
Controversy of posterior reversible encephalopathy syndrome: What
have we learnt in the last 20 years? J Neurol Neurosurg Psychiatry.
89:14–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schweitzer AD, Parikh NS, Askin G, Nemade
A, Lyo J, Karimi S, Knobel A, Navi BB, Young RJ and Gupta A:
Imaging characteristics associated with clinical outcomes in
posterior reversible encephalopathy syndrome. Neuroradiology.
59:379–386. 2017. View Article : Google Scholar : PubMed/NCBI
|
